The effectiveness of ICIs depends on several factors, including PD-L1 expression in tumors, tumor mutation burden, T cell–inflamed tumor microenvironment, C-reactive protein (CRP) level, and the neutrophil-to-lymphocyte ratio (NLR; refs. 9–14). Here, CRP is linked to neoplasm.